Orgenesis Inc. (NASDAQ:ORGS – Get Free Report) shares rose 300% during mid-day trading on Thursday . The stock traded as high as $0.60 and last traded at $0.60. Approximately 100 shares traded hands during trading, a decline of 84% from the average daily volume of 636 shares. The stock had previously closed at $0.15.
Orgenesis Stock Performance
The stock’s fifty day moving average is $0.28 and its two-hundred day moving average is $0.41. The firm has a market cap of $3.10 million, a price-to-earnings ratio of -0.08 and a beta of 3.44.
Orgenesis Company Profile
Orgenesis, Inc is a cell and gene therapy company that develops and commercializes point-of-care manufacturing platforms for autologous and allogeneic therapies. The company offers an end-to-end solution that spans from R&D through clinical and commercial production, targeting applications in oncology, neurology, and various rare diseases. Orgenesis’ technology platforms are designed to streamline the complex processes involved in cell isolation, genetic modification, expansion and cryopreservation.
The company’s flagship offering is its automated Prodigy® platform, which integrates cell processing workflows into a closed, single-use system.
See Also
- Five stocks we like better than Orgenesis
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- When to buy gold (mathematically)
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- GOLD ALERT
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
